Trial · NCT05903924

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

NCT05903924, Phase 3, Completed, Vanda Pharmaceuticals; results first posted 2025-04-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness. Trials, record NCT05903924. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05903924

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
NCT number: NCT05903924
Status: Completed
Phases: Phase 3
Enrollment: 316 participants, actual
Lead sponsor: Vanda Pharmaceuticals
Conditions: Motion Sickness
Interventions: Tradipitant, Placebo
First posted: 2023-06-15
Last updated: 2025-04-04
Results first posted: 2025-04-04

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Prevention of Vomiting Measured by Vomiting Assessment (VA)	1 day	Prevention of vomiting measured by Vomiting Assessment (VA) score. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Prevention of Vomiting Measured by Vomiting Assessment (VA)	1 day		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Prevention of Vomiting Measured by Vomiting Assessment (VA)	Tradipitant High Dose	11	Participants
Prevention of Vomiting Measured by Vomiting Assessment (VA)	Tradipitant Low Dose	19	Participants
Prevention of Vomiting Measured by Vomiting Assessment (VA)	Placebo	40	Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Tradipitant High Dose	106
Overall Study	STARTED	Tradipitant Low Dose	104
Overall Study	STARTED	Placebo	106
Overall Study	COMPLETED	Tradipitant High Dose	105
Overall Study	COMPLETED	Tradipitant Low Dose	104
Overall Study	COMPLETED	Placebo	106
Overall Study	NOT COMPLETED	Tradipitant High Dose	1
Overall Study	NOT COMPLETED	Tradipitant Low Dose	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events9

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Headache	Nervous system disorders	Tradipitant High Dose	10	106
other	Headache	Nervous system disorders	Tradipitant Low Dose	9	104
other	Headache	Nervous system disorders	Placebo	9	106
other	Somnolence	Nervous system disorders	Tradipitant High Dose	9	106
other	Somnolence	Nervous system disorders	Tradipitant Low Dose	6	104
other	Somnolence	Nervous system disorders	Placebo	8	106
other	Fatigue	General disorders	Tradipitant High Dose	12	106
other	Fatigue	General disorders	Tradipitant Low Dose	9	104
other	Fatigue	General disorders	Placebo	6	106

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Tradipitant High Dose	0	106
Total, all-cause mortality	Tradipitant Low Dose	0	104
Total, all-cause mortality	Placebo	0	106
Total, other adverse events	Tradipitant High Dose	29	106
Total, other adverse events	Tradipitant Low Dose	24	104
Total, other adverse events	Placebo	19	106
Total, serious adverse events	Tradipitant High Dose	0	106
Total, serious adverse events	Tradipitant Low Dose	0	104
Total, serious adverse events	Placebo	0	106

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
42150111	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05903924

GET https://conductscience.org/api/trials/v1/NCT05903924/registered

API reference For AI assistants